Rich Nations Now Using Licenses to Cut Medicine Costs

More countries are finding legal ways to make expensive medicines accessible to their people, and the shift is happening faster than anyone expected.

A study published in BMJ Global Health reveals that high-income nations dramatically increased their use of compulsory licenses between 2015 and 2024. These special licenses allow governments to authorize generic drugmakers to produce patented medicines without waiting for the brand-name company's permission.

The numbers tell a striking story. Between 2005 and 2014, wealthy nations pursued just 15% of all compulsory licenses worldwide. That number soared to 54% in the following decade.

Researchers examined 149 compulsory licenses issued by countries across all income levels during the 20-year study period. The medicines covered ranged from cancer treatments to therapies for cystic fibrosis, with a notable spike for Covid-19 medications during the pandemic.

The practice has long been controversial in pharmaceutical circles. Drug companies argue that patents protect the research investments needed to develop new treatments. But governments counter that their citizens shouldn't face impossible choices between financial ruin and health.

The Ripple Effect

This trend signals a fundamental shift in how nations prioritize public health over pharmaceutical profits. When Canada issued its first compulsory license in decades for a Covid-19 treatment, it set a precedent other wealthy nations watched closely.

The increase suggests that governments are becoming more comfortable using tools that were once seen as reserved for poorer countries facing health emergencies. That normalization could reshape negotiations between nations and drug companies going forward.

Patients in countries that issue these licenses gain access to treatments at a fraction of the original cost. Generic versions often sell for 90% less than branded medications, transforming previously unaffordable therapies into realistic options for ordinary families.

The study's authors note that most licenses in the recent decade focused on noncommunicable diseases like cancer, a departure from earlier patterns that concentrated on infectious diseases. This broader application shows governments recognizing that affordable access matters across all medical conditions.

As more nations see their peers successfully using compulsory licenses, the practice may become a standard tool in the public health toolkit rather than a last resort.